Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $9999.0.

  • 60 Degrees Pharmaceuticals' Capital Expenditures fell 2740.14% to $9999.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $60000.0, marking a year-over-year decrease of 6239.97%. This contributed to the annual value of $103773.0 for FY2024, which is 8008.95% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Capital Expenditures stood at $9999.0 for Q3 2025, which was down 2740.14% from $47323.0 recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Capital Expenditures registered a high of $89274.0 during Q2 2024, and its lowest value of -$13596.0 during Q3 2023.
  • Its 4-year average for Capital Expenditures is $20962.7, with a median of $11063.0 in 2023.
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Capital Expenditures plummeted by 85813.95% in 2023, and later surged by 63615.9% in 2024.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Capital Expenditures stood at $31575.0 in 2022, then skyrocketed by 76.72% to $55800.0 in 2023, then tumbled by 75.32% to $13773.0 in 2024, then decreased by 27.4% to $9999.0 in 2025.
  • Its last three reported values are $9999.0 in Q3 2025, $47323.0 for Q2 2025, and $2678.0 during Q1 2025.